• Explore /
  • Poster
  • / Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).

Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).

Abstract Poster

Authors

null

Inna Markovna Chen

Copenhagen University Hospital - Herlev and Gentofte, Herlev, Herlev, Denmark

Inna Markovna Chen , Julia S. Johansen , Susann Theile , Kasper Madsen , Olav Dajani , Torben Lorentzen , Teresa Zimmers , Dorte Nielsen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02767557

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4147)

DOI

10.1200/JCO.2023.41.16_suppl.4147

Abstract #

4147

Poster Bd #

468

Abstract Disclosures

Similar Posters

First Author: Benedikt Westphalen

First Author: Mingfang Xu

First Author: Hongyang Wu

First Author: Jaekyung Cheon